Abstract
Renal cell carcinoma (RCC) is a disease with a variable natural history, sometimes presenting with a very indolent course and other times with an aggressive clinical course and unusual sites of metastasis. Surgical resection for stage I-III tumors represents the standard of care and is the only curative option available to patients. However, 40-50% of patients develop metastatic disease. Prior to the advent of targeted therapy, cytokine therapy was the only treatment for RCC. The administration of high-dose, bolus IL-2 has historically produced consistent, durable responses in a small percentage of patients with advanced RCC. The use of IFN-a is currently limited to combination therapies. Multiple new agents targeting the VEGF pathway have been tested and approved, including sunitinib, sorafenib and bevacizumab, with others waiting in the wings. In the majority of cases these drugs induce disease stabilization with eventual disease progression. Hence additional new pathways are being targeted and studied. Mechanisms of drug resistance, novel combinations, sequences and schedules are the focus of current clinical investigations. This review provides an updated list of the novel targeted agents in advanced clinical development for metastatic RCC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1817-1827 |
| Number of pages | 11 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 9 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2009 |
| Externally published | Yes |
Fingerprint
Keywords
- c-kit
- HDAC
- HIF-α
- Immunotherapy
- Metastatic renal cell carcinoma
- mTOR
- PDGFR
- Targeted therapy
- VEGF receptor
- VHL
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
Cite this
Update on novel agents in renal cell carcinoma. / Tamaskar, Ila; Pili, Roberto.
In: Expert Review of Anticancer Therapy, Vol. 9, No. 12, 12.2009, p. 1817-1827.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Update on novel agents in renal cell carcinoma
AU - Tamaskar, Ila
AU - Pili, Roberto
PY - 2009/12
Y1 - 2009/12
N2 - Renal cell carcinoma (RCC) is a disease with a variable natural history, sometimes presenting with a very indolent course and other times with an aggressive clinical course and unusual sites of metastasis. Surgical resection for stage I-III tumors represents the standard of care and is the only curative option available to patients. However, 40-50% of patients develop metastatic disease. Prior to the advent of targeted therapy, cytokine therapy was the only treatment for RCC. The administration of high-dose, bolus IL-2 has historically produced consistent, durable responses in a small percentage of patients with advanced RCC. The use of IFN-a is currently limited to combination therapies. Multiple new agents targeting the VEGF pathway have been tested and approved, including sunitinib, sorafenib and bevacizumab, with others waiting in the wings. In the majority of cases these drugs induce disease stabilization with eventual disease progression. Hence additional new pathways are being targeted and studied. Mechanisms of drug resistance, novel combinations, sequences and schedules are the focus of current clinical investigations. This review provides an updated list of the novel targeted agents in advanced clinical development for metastatic RCC.
AB - Renal cell carcinoma (RCC) is a disease with a variable natural history, sometimes presenting with a very indolent course and other times with an aggressive clinical course and unusual sites of metastasis. Surgical resection for stage I-III tumors represents the standard of care and is the only curative option available to patients. However, 40-50% of patients develop metastatic disease. Prior to the advent of targeted therapy, cytokine therapy was the only treatment for RCC. The administration of high-dose, bolus IL-2 has historically produced consistent, durable responses in a small percentage of patients with advanced RCC. The use of IFN-a is currently limited to combination therapies. Multiple new agents targeting the VEGF pathway have been tested and approved, including sunitinib, sorafenib and bevacizumab, with others waiting in the wings. In the majority of cases these drugs induce disease stabilization with eventual disease progression. Hence additional new pathways are being targeted and studied. Mechanisms of drug resistance, novel combinations, sequences and schedules are the focus of current clinical investigations. This review provides an updated list of the novel targeted agents in advanced clinical development for metastatic RCC.
KW - c-kit
KW - HDAC
KW - HIF-α
KW - Immunotherapy
KW - Metastatic renal cell carcinoma
KW - mTOR
KW - PDGFR
KW - Targeted therapy
KW - VEGF receptor
KW - VHL
UR - http://www.scopus.com/inward/record.url?scp=73349107447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73349107447&partnerID=8YFLogxK
U2 - 10.1586/ERA.09.157
DO - 10.1586/ERA.09.157
M3 - Review article
VL - 9
SP - 1817
EP - 1827
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 12
ER -